Wednesday, 18 September 2019

RegeneRx Chinese heart patent gets nod

08 February 2013 | News | By BioSpectrum Bureau

RegeneRx gets Notice of Allowance from Chinese Patent Office

RegeneRx gets Notice of Allowance from Chinese Patent Office

RegeneRx gets Notice of Allowance from Chinese Patent Office

Singapore: RegeneRx Biopharmaceuticals has received a Notice of Allowance of a Chinese patent application for uses of Thymosin beta 4 (TB4) for treating, preventing, inhibiting or reducing heart tissue deterioration, injury or damage in a subject with heart failure disease.

RegeneRx Biopharmaceuticals' claims also include uses for restoring heart tissue in those subjects. The patent will expire July 26, 2026.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Pharma innovation getting inhibited in APAC?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls